CG
ACXP icon

Cutler Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Cutler Group’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2K Sell
60
-55
-48% -$3.58K ﹤0.01% 1786
2023
Q4 		$8K Buy
+115
New +$8.68K ﹤0.01% 2496

Other funds holding ACXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's ACXP Position: Q1 2024 in Review

Cutler Group reduced its Acurx Pharmaceuticals (ACXP) stake by 48% in Q1 2024, selling an estimated $3.58K and leaving 60 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Cutler Group first reported a position in ACXP in Q4 2023 and has held it in 2 quarters since. The position peaked at $8K in Q4 2023. 26 funds tracked by Wall St. Rank hold ACXP as of Q1 2024.

  • Cutler Group held 60 shares of Acurx Pharmaceuticals worth $2K as of Q1 2024.
  • Cutler Group sold 55 Acurx Pharmaceuticals shares in Q1 2024, an estimated $3.58K.
  • Acurx Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1786 holding.
  • Cutler Group first reported a position in Acurx Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • Cutler Group's Acurx Pharmaceuticals position peaked at $8K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.